Lapatinib is a dual inhibitor of the EGF receptor (EGFR) and ErbB2 (IC50s = 19 and 3 nM, respectively).{24151} It inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 μM
英文名:
GSK 572016|GW 572016
库存:
10 mg, 100 mg, 25 mg, 5 mg
供应商:
Cayman
CAS号:
231277-92-2
规格:
This biochemical is available in the following size(s) 10 mg, 5 mg, 50 mg - Please inquire
A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 μM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 μM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 μM); induces apoptosis in NCI-N87 and OD19 cells at 1 μM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab